Hyperparathyroidism
📧 Sign up to get email alerts when something new happens for Hyperparathyroidism.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-07-10Clinical Trial Update: Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years
A completed study evaluated intravenous paricalcitol (Zemplar) for its effect on cardiac morbidity in patients with chronic kidney disease s…
-
FDA approval · 2014-06-24FDA Approved: PARICALCITOL — Original Application (Dr. Reddy's Laboratories Limited)
FDA approved the original application for paricalcitol from Dr. Reddy's Laboratories Limited, enabling a generic version of the drug. This m…
-
CLINICAL_TRIALS withdrawal · 2014-05-21Clinical Trial Update: Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease [NA]
A clinical trial evaluating the effects of Vitamin D on renal blood flow, proteinuria, and inflammation in chronic kidney disease was withdr…
-
CLINICAL_TRIALS trial_result · 2014-05-14Clinical Trial Update: Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism [NA]
Clinical trial update on suspected deficient activation of vitamin D in patients with secondary hyperparathyroidism; study completed with re…
-
CLINICAL_TRIALS trial_result · 2014-05-06Clinical Trial Update: Observation of Histological Changes in Parathyroid Adenomas Following High Intensity Focused Ultrasound (HIFU) Treatment Procedure [NA]
A completed Theraclion-sponsored clinical trial reports histological changes in parathyroid adenomas following high intensity focused ultras…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2014-05-06Clinical Trial Update: Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Secondary Hyperparathyroidism [NA]
A clinical trial evaluating a High Intensity Focused Ultrasound (HIFU) device to treat secondary hyperparathyroidism has been withdrawn.
-
CLINICAL_TRIALS research · 2014-04-16Clinical Trial Update: Differentially Expressed Proteins in Sporadic Parathyroid Tumors
This clinical trial update reports on differentially expressed proteins in sporadic parathyroid tumors. The work is in the setting of primar…
-
CLINICAL_TRIALS trial_result · 2014-04-14Clinical Trial Update: How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis [Phase 4]
A Phase 4 trial evaluated the effects of vitamin D analogues on endothelial cells in patients on dialysis with secondary hyperparathyroidism…
-
CLINICAL_TRIALS trial_result · 2014-04-07Clinical Trial Update: Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in Hemodialysis Patients [Phase 4]
This document reports the completion of a Phase 4 clinical trial evaluating the acute effects of cinacalcet on arterial stiffness and ventri…
-
FDA approval · 2014-03-27FDA Approved: PARICALCITOL — Original Application (Bionpharma Inc.)
FDA approved Bionpharma Inc.'s original application for paricalcitol, a generic paricalcitol product. This approval supports the use of pari…
-
CLINICAL_TRIALS trial_result · 2014-03-12Clinical Trial Update: 20070360 Incident Dialysis [Phase 4]
Phase 4 clinical trial update for incident dialysis in chronic kidney disease with secondary hyperparathyroidism; study completed with resul…
-
CLINICAL_TRIALS trial_result · 2014-02-28Clinical Trial Update: Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation
An observational program evaluating Zemplar (paricalcitol) for secondary hyperparathyroidism in end-stage renal disease patients on hemodial…
-
CLINICAL_TRIALS trial_result · 2014-02-19Clinical Trial Update: Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis
This completed clinical trial evaluated patient management practices and quality of life for paricalcitol capsules in treating secondary hyp…
-
CLINICAL_TRIALS trial_result · 2014-02-11Clinical Trial Update: ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism [Phase 4]
Amgen completed a Phase 4 clinical trial update aimed at optimizing treatment of secondary hyperparathyroidism.
-
CLINICAL_TRIALS trial_result · 2014-01-22Clinical Trial Update: E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events [Phase 3]
Phase 3 trial update for cinacalcet hydrochloride (E.V.O.L.V.E. Trial) assessing its impact on cardiovascular events in secondary hyperparat…
-
CLINICAL_TRIALS trial_result · 2013-12-04Clinical Trial Update: Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease [Phase 2]
Phase 2 bone biopsy study in dialysis patients with secondary hyperparathyroidism; results were posted in 2013.
-
CLINICAL_TRIALS research · 2013-11-14Clinical Trial Update: PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice
This clinical trial update reports a completed prospective descriptive observational study (NCT00928408) reviewing the real-world use of Mim…
-
CLINICAL_TRIALS trial_result · 2013-11-13Clinical Trial Update: Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism [Phase 4]
Phase 4 clinical trial evaluating cinacalcet for effects on vascular arterial stiffness in peritoneal dialysis patients with secondary hyper…
-
CLINICAL_TRIALS trial_result · 2013-11-11Clinical Trial Update: Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease [Phase 3]
A Phase 3 trial evaluating the effect of vitamin D3 supplementation on inflammation markers in high-risk cardiovascular patients with chroni…
-
FDA approval · 2013-10-17FDA Approved: ZEMPLAR — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for ZEMPLAR (paricalcitol) submitted by AbbVie Inc., indicating an approved update to its labeling/i…
-
CLINICAL_TRIALS trial_result · 2013-10-16Clinical Trial Update: Effect of Vitamin D Treatment in Primary Hyperparathyroidism [Phase 2, Phase 3]
Phase 2 and Phase 3 trial results evaluating Vitamin D therapy in primary hyperparathyroidism have been completed, with results posted in 20…
-
CLINICAL_TRIALS trial_result · 2013-08-26Clinical Trial Update: Near Infrared Fluorescent Imaging in Thyroid and Parathyroid Surgery With the Fluobeam(TM) System of Fluoptics [Phase 1]
Phase 1 trial evaluating near-infrared fluorescent imaging with the Fluobeam system to aid thyroid and parathyroid surgery in patients with …
-
CLINICAL_TRIALS research · 2013-08-13Clinical Trial Update: A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients
This is a completed prospective cohort study describing how persistent hyperparathyroidism evolves in kidney transplant recipients.
-
CLINICAL_TRIALS trial_result · 2013-08-13Clinical Trial Update: Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice
A pediatric trial evaluating the safety of vitamin D receptor activators in chronic kidney disease stage 5 patients on peritoneal dialysis w…
-
FDA approval · 2013-07-22FDA Approved: ZEMPLAR — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for Zemplar (paricalcitol) from AbbVie Inc.